• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Trial Recovery Requires More Technology Support from Sponsors/CROs, Sites Say

Trial Recovery Requires More Technology Support from Sponsors/CROs, Sites Say

July 20, 2020

Site staff believe more telecommunication technology will be needed to get trials back on their feet post-pandemic and say they need help from sponsors and CROs to implement alternative approaches to in-person patient visits, according to a new report.

Respondents to a survey conducted by Clinical SCORE said it will take 5 to 6 months on average to recover from financial losses and return the number of trials being activated to pre-COVID-19 levels. Financial recovery will require scaling up remote and virtual visits to make up for loss of staff during the pandemic.

Most of the 255 survey respondents expect the number of in-person site visits to decline, and 62 percent said telephone communications will see the greatest increase, followed by virtual visits (e.g., web-based video visits) at 51 percent and remote visits conducted at facilities other than the trial sites at 47 percent. Home visits also will increase, according to 20 percent of respondents.

Three-quarters of respondents said they need more support from sponsors for the protocol changes required to implement virtual and remote visits as well as funding to do so. One-third called for CRO assistance in executing remote visits.

To read the report, click here: https://bit.ly/32s8ZBR.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing